focus -WSS

focus

author：Wikipedia 2025-08-19 20:44:56 - browse：86742

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： A preacher's new calling: Diversifying neuroscience research

WSS

Study suggests new cause of Down syndrome: cells linked to aging

Gene therapy denied for Afghan refugee whose father aided U.S.

Weight loss drug costs may need more research, senator suggests

Poor hospice wound care hurts patients and families

Does good food count as health care? Study aims to find out

U.K. considers world's first use of meningitis vaccine to address gonorrhea

focus

focus

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Childhood cancer progress stalls for Black, Hispanic kids: Report

Anesthesiologist group: stop taking Ozempic before surgery

Ransomware attacks on hospitals: Study outlines patient impact

Trump demands the U.S. pay no more for drugs than other countries … again

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

The cancer drug shortage isn’t new — and neither are the solutions

Astellas still sees hope in its gene therapy after four deaths

Wildfire smoke exposes gaps in outdoor worker protections

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

hotspot

Profiling embryos to choose those with higher IQs is almost a reality

Gene therapy denied for Afghan refugee whose father aided U.S.

Life science postdocs should get big pay hike, NIH panel says

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

In key trial, Verve's treatment lowers cholesterol levels in patients

Medicare Advantage coverage denials need scrutiny, senators say

focus

explore

hotspot

entertainment